drugset
drugset / Trial / NCT04971109

Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days

NCT04971109 ↗

Phase 3 Completed 467 enrolled SIGA Technologies United States Department of Defense · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a study to assess the safety, tolerability, and PK of oral TPOXX 600 mg when administered twice daily (BID) for 28 days in adult subjects.

Timeline

Start
2022-03-29
Primary completion
2023-05-12
Completion
2023-05-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tecovirimat Small molecule 600 mg Oral

Indications

smallpox